Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma

NCT07164313 is registered in ClinicalTrials.gov with Zymeworks BC Inc. as lead sponsor.

NCT NCT07164313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07164313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma
Lead sponsor
Zymeworks BC Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
October 21, 2025
Completion date
May 31, 2028
Enrollment
140 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

germ cell tumor, hepatocellular carcinoma, squamous cell non-small cell lung cancer